Skip to content

Author

T. Vincken

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Cost-effectiveness analysis of ribociclib plus an aromatase inhibitor versus abemaciclib plus endocrine therapy in the adjuvant treatment of HR+/HER2- early breast cancer: a Canadian payer perspective.

Aim: Ribociclib and abemaciclib, cyclin-dependent kinase 4/6 inhibitors, are adjuvant treatments for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC). In the Phase III NATALEE trial, ribociclib plus an aromatase inhibitor (AI) significantly improved in...

D. Soliman, C. Brezden-Masley, S. Sehdev et al. · 0 citations
Open access Oct 2026

Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2- Early Breast Cancer (EBC): A Canadian Payer Perspective.

BACKGROUND Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have transformed the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Ribociclib plus an aromatase inhibitor (AI) was approved in Canada as adjuvant treatment for high-risk stage II-III ea...

D. Soliman, C. Brezden-Masley, S. Sehdev et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.